IOVA - Iovance Biotherapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development71,61526,94115,470
Selling General and Administrative21,26226,69812,390
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-92,877-53,639-27,860
Income from Continuing Operations
Total Other Income/Expenses Net813745200
Earnings Before Interest and Taxes-92,064-52,894-27,660
Interest Expense---
Income Before Tax-92,064-52,894-27,660
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-92,064-52,894-27,660
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-92,064-52,894-27,660
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-92,064-102,348-27,660